Skip to main content
OpenTrials
Completed

NCT Number: NCT06778733

Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders

In the present study we examined the effect of addition of CC to a low dose gonadotropin (150 IU/day) / GnRH antagonist protocol in comparison to a high gonadotropin dose (300 IU/day) regiment (short protocol) in women with poor ovarian responce (POR).

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

Aretaieion University Hospital, Athens, Attica, Greece

Loading trial locations.

About this study

22 patients diagnosed with poor ovarian response, aged 35-43 years, were enrolled in the study. The definition of poor response was based on the presence of at least one of the following criteria: Age equal or over 40 years old or other cause of subfertility, AFC less than 5-7, AMH 0.5-1,1ng/ml , a previous POR (≤3 oocytes with a conventional stimulation protocol or cancellation due to poor response) . All patients received appropriate counselling . Early follicular phase FSH and estradiol (E2) were measured prior to the initiation of treatment. All women had measurements of serum FSH and estradiol and a pelvic sonogram on the second day of their cycle. Providing that serum FSH level was less than 16 mIU/ml and estradiol level less than 70 pg/ml on cycle day2 , ovarian stimulation was initiated with 300 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of recombinant FSH and recombinant LH. All patients were re-evaluated on day 5 of the stimulation, and dosage adjustments were made and the antagonists (Cetrorelix or ganirelix 0.25 mg/day) were initiated when at least one follicle reached a diameter of 14mm . When at least 2 follicles reached an average diameter of 18 mm, final oocyte maturation was triggered with 10,000IU of hCG ( Ovitrelle, Greece Inc.). Oocyte retrieval was performed 34 to 36 hours later. All patients underwent ICSI. Patients with successful fertilization underwent embryo transfer under sonographic guidance on day 5 after retrieval. Serum β-hCG levels were measured 12 days after oocyte retrieval, and clinical pregnancy was confirmed by transvaginal ultrasound 14 days later. Ongoing pregnancy was confirmed at 12 weeks by ultrasound. In case of negative pregnancy test result the same participants received CC (100 mg/day) from day 3 to day 7 of the menstrual cycle, in combination with low-dose gonadotropins (150 IU/day) until the day of hCG administration. The primary outcome measure was ongoing pregnancy rates. Secondary outcomes included the number of follicles, the number of mature oocytes, fertilization rate, total number of embryos and embryo quality in each group. Furthermore, we included biochemical pregnancy rates and miscarriage as secondary outcomes as well.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

The inclusion criteria, established by the European Society of Human Reproduction and Embryology (ESHRE), define POR as the presence of at least two of the following features, had to be met:

  • Advanced maternal age (≥40 years) or any other risk factor for POR
  • A previous POR (≤3 oocytes with a conventional stimulation protocol)
  • An abnormal ovarian reserve test (Day 3 follicle-stimulating hormone (FSH) > 12 mIU/ml
  • Anti-Müllerian hormone (AMH) < 2ng/ml).

Exclusion criteria

The succesful ongoing pregnancy after the first stimulation.

Treatment and study plan

Clomiphane citrate

Drug

Clomiphene citrate 100mg/day from day 3 to day 7 of the cycle (5 days) will be added to the low-dose (150 IU) short GnRh antagonist protocol (recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE))

Other names: Clomiphene citrate 50mg/tab, Serpafar 50mg/tab

recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)

Drug

All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.

Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)

Other names: Gonal-f 150 Iu/day, Gonal-f 300 IU/day

Primary outcomes

  1. Ongoing pregnancy rates

    Time frame: 28 months from start of study

    succesfull clinical pregnancy after performing ultrasound on 12 weeks of pregnancy

Secondary outcomes

  1. Number of follicles

    Time frame: 24 months from start of study

    Calculated on the day of triggering

  2. Number of mature oocytes

    Time frame: 24 months from start of study

    MII

  3. Fertilization rate

    Time frame: 24 months from start of study

    Percentage

  4. Total number of embryos in each group

    Time frame: 24 months from start of study

    Total number of embryos

  5. Biochemical pregnancy rates

    Time frame: 24 months from start of study

    Absence of clinical pregnancy

  6. Miscarriage rates

    Time frame: 28 months from start of study

    Percentage of pregnancies that did not reach viability

Sponsors and collaborators

Lead sponsor

University of Athens

Other

Registry information

Official study title

The Effect of Clomiphene Citrate Administration in Combination with Low Dose (150 IU) of Gonadotropins Vs High Dose Gonadotropin Protocol in Poor Responders. Impact on Stimulation Characteristics and Pregnancy Outcome.

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jan 16, 2025
Registry last updated
Jan 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.